Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385574 | 0.88 | TSHR (0.53) | MAPTSMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL1383419 | 0.86 | SMN1; SMN2 (0.46) | MAPTSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL1382958 | 0.85 | MAPT (0.51) | MAPTSMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL1383157 | 0.84 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL1385723 | 0.83 | PTK2 (0.63) | ALDH1A1 | |
| SCHEMBL1384279 | 0.83 | PTK2 (0.50) | MAPTALDH1A1TSHRPOLB | |
| SCHEMBL1384984 | 0.81 | PTK2 (0.50) | ALDH1A1KDM4E | |
| SCHEMBL1383158 | 0.79 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL1385576 | 0.77 | MAPT (0.59) | MAPTSMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL1383880 | 0.74 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4790704-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-08-28 | — | — | US | claimed |
| EP-1748987-A2 | 2-PROPENE-1-ONES AS HSP 70 INDUCERS | Torrent Pharmaceuticals Ltd (IN) | 2007-02-07 | — | — | EP | claimed |
| WO-2005097746-A2 | 2-PROPENE-1-ONES AS HSP 70 INDUCERS | TORRENT PHARMACEUTICALS LTD (IN) | 2005-10-20 | — | — | WO | claimed |
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | HSPB1, HSF1, HSPE1 | MAPT 71/4885SMN1; SMN2 315/4885HTT 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.